Question 1

What is Shanghai Junshi Biosciences?

Accepted Answer

Shanghai Junshi Biosciences is a Company.

Question 2

How often does Shanghai Junshi Biosciences appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 14 articles.

Question 3

When was Shanghai Junshi Biosciences first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was Shanghai Junshi Biosciences last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is Shanghai Junshi Biosciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Shanghai Junshi Biosciences in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Shanghai Junshi Biosciences?

Accepted Answer

Toripalimab approved for urothelial carcinoma (May 21, 2026, 6 articles).

Question 8

How did the "Toripalimab approved for urothelial carcinoma" event impact Shanghai Junshi Biosciences?

Accepted Answer

The China — National Medical Products Administration (NMPA) approved the new drug application (NDA) for toripalimab in combination with disitamab vedotin for HER2-expressing urothelial carcinoma, marking the 13th approved indication for toripalimab in the Chinese Mainland. This approval is a significant milestone for Shanghai Junshi Biosciences>>> and deepens its impact across the immunotherapy landscape.

Question 9

How did the "Junshi Biosciences licenses roconkibart to Fosun Wanbang" event impact Shanghai Junshi Biosciences?

Accepted Answer

Shanghai Junshi Biosciences Co., Ltd has entered into a licensing agreement with Fosun International — Fosun Wanbang Pharma Group for roconkibart, receiving an upfront payment and potential milestone payments and royalties. This collaboration expands its autoimmune disease treatment portfolio and validates its innovative capabilities.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.